Intelligent Bio Solutions Inc(INBS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
October 7 at 4:00 PM ET (Korea 10/8 05:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -9.45 | Insider Own | 2.99% | Shs Outstand | 3.3M | Perf Week | -4.79% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | 21.62% | Insider Trans | - | Shs Float | 3.2M | Perf Month | -26.05% |
| Enterprise Value | 0.00B | PEG | - | EPS next Q | -1.31 | Inst Own | 5.47% | Short Float | 3.71% | Perf Quarter | -28.05% |
| Income | -0.01B | P/S | 1.25 | EPS this Y | 38.63% | Inst Trans | -1.04% | Short Ratio | 0.75 | Perf Half Y | -40% |
| Sales | 0.00B | P/B | 0.84 | EPS next 5Y | - | ROA | -121% | Short Interest | 0.12M | Perf YTD | -83.32% |
| Book/sh | 1.9 | P/C | 1.32 | EPS past 3/5Y | 81.2% 65.06% | ROE | -292.25% | 52W High | -93.61% ($24.90) | Perf Year | -85.41% |
| Cash/sh | 1.2 | P/FCF | - | Sales past 3/5Y | 49.68% - | ROIC | -173.06% | 52W Low | 4.61% ($1.52) | Perf 3Y | -96.53% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 54.22% | Gross Margin | 21.02% | Volatility(W/M) | 9.47% 7.69% | Perf 5Y | -99.97% |
| Dividend TTM | - | EV/Sales | 0.68 | Sales Y/Y TTM | 38.09% | Oper. Margin | -306.76% | ATR (14) | 0.17 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.35 | EPS Q/Q | 68.13% | Profit Margin | -294.91% | RSI (14) | 30.02 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.44 | Sales Q/Q | 35.78% | SMA20 | -12.3% ($1.81) | Beta | 4.5 | Target Price | $12 |
| Payout | - | Debt/Eq | 0.33 | Earnings | 2026/8/19 | SMA50 | -24.5% ($2.11) | Rel Volume | 0.13 | Prev Close | $1.58 |
| Employees | 58 | LT Debt/Eq | 0.3 | EPS/Sales Surpr. | - -1.64% | SMA200 | -58.89% ($3.87) | Avg Volume(3M) | 0.16M | Price | $1.59 |
| IPO | 2020/12/23 | Option/Short | No/Yes | Trades | 173 | Volume | 20,766 | Change | 0.63% |
Intelligent Bio Solutions () is a medical-device micro-cap that holds a fingerprint drug screening system capable of diagnosing drug use from sweat on a fingertip within 10 minutes. It supplies a non-invasive testing solution, which combines a single-use cartridge with a portable reader, to the workplace, roadside, and corrections facility markets.
Over the past 1 year, on the lower side
94% below its 1-year high.
Traded less than usual That is 13% of its average volume.
INBS has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +38.6% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $125. Peers typically go for $155.
Tap to view numbers
Not enough quarters to judge yet
Only 1 quarter(s) reported, so no grade yet.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -100.0%. The S&P 500 did +77% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 5.5%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
VXF Vanguard Extended Market Index ETF <0.01% It ranks #128 of 143 in the industry
Based on market cap of $5M.
VNRX#126 VolitionRX Ltd $6M PER - 
NVNO#127 enVVeno Medical Corp $6M PER - INBS#128 Intelligent Bio Solutions Inc $5M PER - 
VVOS#129 Vivos Therapeutics Inc $5M PER - 
POAS#130 Phaos Technology (Cayman) Holdings Ltd $5M PER - 
FAQ
What kind of company is INBS?
INBS belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of INBS?
The market cap of INBS is approximately $5M, ranking 5,663 within its sector.
What is the 52-week high and low for INBS?
INBS has recorded a 52-week high of $24.90 and a low of $1.52.
